Recent News

• 03.03.2025 - ArriVent BioPharma Reports Full Year 2024 Financial Results
• 03.03.2025 - ArriVent BioPharma Reports Full Year 2024 Financial Results
• 01.22.2025 - ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
• 01.22.2025 - ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
• 11.14.2024 - ArriVent BioPharma Reports Third Quarter 2024 Financial Results
• 11.14.2024 - ArriVent BioPharma Reports Third Quarter 2024 Financial Results

Recent Filings

• 03.03.2025 - EX-99.1 EX-99.1
• 03.03.2025 - 8-K Current report
• 03.03.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.03.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities